CD8A and cancer: This unique property of augmenting the number of CD8+ T lymphocytes and not other lymphocytes (Table 10) by monospecific but not by polyreactive anti-HLA-E mAbs strongly clarifies the potential of the monospecific anti-HLA-E mAbs for passive immunotherapy of cancer.